Functional Decline Associated with Irinotecan as the Central Driver of Nutritional Deterioration in Advanced Colorectal Cancer: An Analysis Based on PG-SGA
Preprint
- 13 March 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Background/Objectives: Malnutrition is highly prevalent in patients with advanced colorectal cancer (CRC) and is associated with poorer treatment tolerance, reduced quality of life, and worse clinical outcomes. Chemotherapy regimens incorporating irinotecan are commonly used in later treatment lines but present a distinct toxicity profile characterized mainly by gastrointestinal symptoms and functional decline, which may negatively affect nutritional status. This study aimed to evaluate the impact of irinotecan-containing chemotherapy regimens on nutritional status and functional capacity in patients with advanced CRC using the Patient-Generated Subjective Global Assessment (PG-SGA). Methods: A cross-sectional observational study was conducted in 91 adult patients with histologically confirmed stage III–IV colorectal adenocarcinoma undergoing active systemic chemotherapy between November 2023 and June 2024. Demographic and clinical variables, treatment regimens, and exposure to irinotecan were recorded. Nutritional status was assessed using the PG-SGA, and body composition was evaluated by multifrequency bioelectrical impedance analysis. Associations between irinotecan exposure and nutritional, functional, and symptom-related variables were analyzed using χ² or Fisher’s exact tests. Results: Thirteen patients (14.3%) received irinotecan-containing regimens, most frequently combined with FOLFOX. Patients exposed to irinotecan presented higher PG-SGA scores, indicating a greater nutritional burden. Although most gastrointestinal symptoms did not reach statistical significance, early satiety (p = 0.041) and functional deterioration (p = 0.039) were significantly associated with irinotecan administration, while nausea (p = 0.089) and vomiting (p = 0.087) showed trends toward significance. The subgroup treated with FOLFOX–irinotecan also demonstrated a higher frequency of functional impairment compared with those receiving FOLFOX alone. Conclusions: Irinotecan-containing chemotherapy regimens in advanced CRC are associated with a distinct pattern of nutritional deterioration primarily driven by functional decline and gastrointestinal symptoms affecting food intake. Systematic nutritional assessment using validated tools such as the PG-SGA may allow early identification of vulnerable patients and support the implementation of timely multimodal interventions aimed at improving treatment tolerance and clinical outcomes.Keywords
All Related Versions
- Version 1, 2026-03-13, Preprints
- Published version: Cancers, 18 (7), 1140.
This publication has 31 references indexed in Scilit:
- Multimodal interventions for cachexia managementCochrane Database of Systematic Reviews, 2023
- Predictive validity of GLIM malnutrition diagnosis in patients with colorectal cancerJournal of Parenteral and Enteral Nutrition, 2023
- Impact of sarcopenia on surgical and oncologic outcomes of laparoscopic surgery for colorectal cancerAsian Journal of Surgery, 2022
- Patient-Generated Subjective Global Assessment (PG-SGA) predicts length of hospital stay in lung adenocarcinoma patientsBritish Journal of Nutrition, 2021
- Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)Digestive and Liver Disease, 2020
- Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre studyEuropean Journal of Cancer, 2019
- Agreement between PG-SGA category and fat-free mass in colorectal cancer patientsClinical Nutrition ESPEN, 2018
- ESPEN guidelines on nutrition in cancer patientsClinical Nutrition, 2017
- Conséquences de la diminution de la masse musculaire sur la tolérance des traitements anticancéreuxBulletin du Cancer, 2016
- Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based studyThe Lancet Oncology, 2008